GC
MRSN

Grimes & Company’s Mersana Therapeutics MRSN Stock Holding History

Grimes & Company’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-563
Closed -$4.84K – 422
2025
Q1 		$4.84K Sell
563
-37
-6% -$571 ﹤0.01% 368
2024
Q4 		$21.4K Hold
600
– – ﹤0.01% 380
2024
Q3 		$28.3K Hold
600
– – ﹤0.01% 362
2024
Q2 		$30.1K Sell
600
-14
-2% -$1.01K ﹤0.01% 344
2024
Q1 		$68.8K Sell
614
-12
-2% -$1.19K ﹤0.01% 334
2023
Q4 		$36.3K Sell
626
-19
-3% -$764 ﹤0.01% 324
2023
Q3 		$20.5K Buy
645
+15
+2% +$713 ﹤0.01% 300
2023
Q2 		$51.8K Buy
630
+6
+1% +$878 ﹤0.01% 301
2023
Q1 		$64.1K Buy
624
+13
+2% +$1.82K ﹤0.01% 290
2022
Q4 		$89.5K Buy
611
+4
+0.7% +$676 ﹤0.01% 279
2022
Q3 		$103K Buy
607
+10
+2% +$1.63K 0.01% 264
2022
Q2 		$69K Buy
597
+22
+4% +$2.07K ﹤0.01% 268
2022
Q1 		$57K Buy
+575
New +$67.2K ﹤0.01% 296

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Grimes & Company's MRSN Position: Q2 2025 in Review

Grimes & Company sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 563 shares — an estimated $4.84K sold.

Grimes & Company first reported a position in MRSN in Q1 2022 and held it in 13 quarters. The position peaked at $103K in Q3 2022. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Grimes & Company reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Grimes & Company sold 563 Mersana Therapeutics shares in Q2 2025, an estimated $4.84K.
  • Grimes & Company first reported a position in Mersana Therapeutics in Q1 2022 and held it in 13 quarters.
  • Grimes & Company's Mersana Therapeutics position peaked at $103K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Grimes & Company's 13F filing for Q2 2025, filed 22 Jul 2025.